GSK expands gynecologic cancer portfolio with Hansoh deal

21 October 2023
gsk_london_hq

UK pharma major GSK (LSE: GSK) has entered into an exclusive license agreement with Chinese biopharma firm Hansoh Pharma (HKEX: 03692) for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC), which is currently in Phase I (NCT05263479) clinical trials in China.

Under the accord, GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress development and commercialization of HS-20089. The news pushed Hansoh’s shares up as much as 3% to HK$11.36.

Financial terms of the agreement

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology